Adoptive cell therapy using engineered natural killer cells

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer

(2018) Rohtesh S. Mehta et al.   Frontiers in Immunology

Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells

(2017) Maria Carmen Ochoa et al.   IMMUNOLOGY AND CELL BIOLOGY

Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity

(2017) E Liu et al.   LEUKEMIA

Engineering Natural Killer Cells for Cancer Immunotherapy

(2017) Katayoun Rezvani et al.   MOLECULAR THERAPY

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Panel OKs CAR T Therapy for Leukemia

(2017)   Cancer Discovery

Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation

(2016) T. Sekine et al.   BLOOD

Natural Killer Cells for Immunotherapy – Advantages of the NK-92 Cell Line over Blood NK Cells

(2016) Hans Klingemann et al.   Frontiers in Immunology

Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy

(2015) E. Sotillo et al.   Cancer Discovery

Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15

(2014) M. Imamura et al.   BLOOD

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein

(2014) V. Bachanova et al.   BLOOD

Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide

(2014) I. S. Nijhof et al.   HAEMATOLOGICA

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies

(2013) H. E. Kohrt et al.   BLOOD

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

HLA-C–Dependent Prevention of Leukemia Relapse by Donor ActivatingKIR2DS1

(2012) Jeffrey M. Venstrom et al.   NEW ENGLAND JOURNAL OF MEDICINE

Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients

(2011) A. Curti et al.   BLOOD

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia

(2010) S. Cooley et al.   BLOOD

NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects

(2010) J. A. Olson et al.   BLOOD

Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy

(2009) H. Fujisaki et al.   CANCER RESEARCH

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia

(2008) S. Cooley et al.   BLOOD

MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response

(2008) M. Yawata et al.   BLOOD

Human natural killer cells

(2008) M. A. Caligiuri   BLOOD

Permanent silencing of NKG2A expression for cell-based therapeutics

(2008) Constança Figueiredo et al.   JOURNAL OF MOLECULAR MEDICINE-JMM

Up on the tightrope: natural killer cell activation and inhibition

(2008) Lewis L Lanier   NATURE IMMUNOLOGY